Fra-1, a member of the activator protein 1 (AP-1) family, is overexpressed in triple-negative breast cancer (TNBC) and plays crucial roles in tumor growth. Here we report the identification of 118 proteins interacting with endogenous chromatinbound Fra-1 in TNBC cells, highlighting DDX5 as the most enriched Fra-1-interacting protein. DDX5, a previously unrecognized protein in the Fra-1 transcriptional network, shows extensive overlap with Fra-1 cistrome and transcriptome that are highly associated with the TNBC cell growth. We provide evidence that DDX5 expression enhances Fra-1 transcriptional activity and potentiates Fra-1-driven cell proliferation. Furthermore, we show that the DDX5 target gene signature predicts poor clinical outcome in breast cancer patients. DDX5 protein level was higher in triple-negative basallike tumors than in non-basal-like tumors, including luminal A, luminal B, and HER2-enriched subtypes. Collectively, by combining proteomic and genomic approaches we reveal a role for DDX5 as a regulatory protein of Fra-1 signaling and suggest DDX5 as a potential therapeutic target for TNBC.
Introduction
Fra-1 (FOSL1), a member of the activator protein 1 (AP-1) family, plays essential roles in diverse aspects of tumor development and metastasis [1] [2] [3] . It associates with Jun proteins (c-Jun, JunB, and JunD) to form heterodimeric AP-1 transcription factor complexes [4] . Like other AP-1 proteins, Fra-1 regulates target gene expression through binding via its basic leucine zipper (bZIP) domain to specific DNA sequences called TPA responsive elements (TREs) and subsequent recruitment of coregulators [5] . Thus, protein-protein interactions are fundamental to the mechanism of Fra-1 regulation of gene expression.
Fra-1-deficient mice die between embryonic day 10.0 (E10.0) and E10.5 [6] , revealing the essential nature of Fra-1. Fra-1 has been suggested to contribute to an important tumor cell feature and to participate in regulation of the migratory or invasive capabilities of various cancer cells [1, 3, [7] [8] [9] . The association between Fra-1 expression and breast cancer is well established. In general, Fra-1 is undetectable in normal breast tissue samples, in contrast to the abundant Fra-1 expression observed in breast carcinoma samples [10] . Our recent studies showed that Fra-1 is highly expressed in triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer, compared to other subtypes of breast cancer [11] . Due to a lack of targeted therapies, chemotherapy is the primary systemic therapy for patients with TNBC. Patients with TNBC tumors experience often relapse, and within a shorter time frame, and have poor prognosis compared to other tumor subtypes. Importantly, we have shown that high Fra-1 expression is associated with poor clinical outcome of breast cancer [11] . Moreover, Fra-1 has also been identified as a key regulator of metastasis in a rodent model system and a zebrafish tumor xenograft model [2, 11] . Emerging data also suggest that Fra-1 is a key regulator to drive epithelial-mesenchymal transition (EMT), explaining the increased invasive and metastatic capabilities of tumor cells [8, 12] . DDX5, also known as p68, is a member of the DEADbox protein family of RNA helicases [13] . It exhibits significant similarity to DDX17 (p72) and these two proteins co-localize and interact in cells [14] . In addition to its established role in RNA processing, DDX5 influences various cellular processes, including cancer progression [15] . DDX5 acts as a transcriptional coactivator for a variety of transcription factors, including androgen and estrogen receptors [16] , p53 [17] , and MyoD [18] . In addition, DDX5 interacts with long non-coding RNAs (lncRNAs) to modulate gene expression [19] , and regulates the transcription of miRNAs [20] . DDX5 has been shown to enhance the tumorigenic potential of breast cancer cells in an animal breast tumor model by activating TCF4 gene expression [21] . Recently, DDX5 was shown to be frequently amplified in ERBB2-positive breast tumors and to promote cell proliferation [22] . DDX5 is highly expressed in a wide range of cancers such as prostate, colon, and breast cancer [23] [24] [25] , although its in vivo targets are not fully characterized.
The nature and identity of Fra-1 interacting protein complexes are largely unknown, as is the precise mechanism of Fra-1-mediated gene regulation. We identified 118 Fra-1-binding partners on chromatin followed by functional validation of DDX5. We found DDX5 as a major protein associated with Fra-1. Using chromatin immunoprecipitation collaborated with next-generation sequencing (ChIPseq) and RNA sequencing (RNA-seq) analyses, we show that DDX5 chromatin binding overlaps extensively with Fra-1 binding at the global level and that they share a substantial number of downstream target genes. We provide evidence that DDX5 expression enhances Fra-1 activation and potentiates its downstream signaling, associated with enhanced Fra-1-driven cell proliferation. Overall, our results unravel a novel biological function of DDX5 as a transcriptional coactivator of AP-1, and further add to the role of DDX5 in breast cancer.
Results
Identification of endogenous Fra-1-associated proteins by RIME RIME (Rapid immunoprecipitation mass spectrometry of endogenous proteins), which is an unbiased proteomic approach, was used to identify Fra-1-associated proteins on chromatin in BT549 TNBC cells, which express high levels of Fra-1 [11] . Endogenous Fra-1 was immunoprecipitated from three independent biological replicates and subjected to quantitative mass spectrometry. We identified 118 Fra-1-interacting proteins that were significantly enriched over IgG IP control (FDR <0.05) (Fig. 1a and Supplementary  Fig. 1 ). The known Fra-1 interaction partners, c-Jun (Jun), JunB, and JunD, were all among the most highly enriched proteins, validating the applied protocol for identification of Fra-1-interacting proteins. Several well-characterized coactivators such as NCOA5, THRAP3, and NONO were identified as Fra-1 interactors. PANTHER protein class analysis revealed 13 groups, including 50 nucleic acidbinding proteins and 13 transcription factors (Fig. 1b and Supplementary Table 1 ). Figure 1c shows the peptide coverage from Scaffold [26] for six selected Fra-1-associated proteins. The interaction between Fra-1 and these proteins was validated by co-immunoprecipitation (co-IP) in BT549 cells (Fig. 1d ).
DDX5 and Fra-1 cistromes overlap
The RNA helicase DDX5, also known as p68, is shown to be the most enriched Fra-1-associated protein (Supplementary Fig. 1 ). Notably, we also identified the DDX5 highly related paralog, DDX17 (p72), as a Fra-1-interacting protein (Fig. 1a) . DDX17 is known to interact with DDX5 [27] , further validating the interactome data. The interaction between Fra-1 and DDX5 was validated by co-IP and reverse co-IP in TNBC cell lines ( Fig. 2a and Supplementary Fig. 2a) . Given that Fra-1 and c-Jun heterodimerization is required for DNA binding, we assayed the interaction of c-Jun with DDX5 using co-IP. Importantly, DDX5 interacts with c-Jun in the three TNBC cell lines ( Supplementary  Fig. 2b ).
Genome-wide profiling of Fra-1-and DDX5 DNAbinding sites in BT549 cells identified 30571 Fra-1-binding sites and 10836 DDX5-binding sites, respectively (Fig. 2b) . The majority (62%) of DDX5-binding regions were also identified as Fra-1-binding regions (Fig. 2b) , as exemplified for the binding to the known Fra-1 target gene CLCA2 [11] (Fig. 2c) . We validated, by ChIP-qPCR, the co-localization of Fra-1 and DDX5 for five selected regions (Supplementary Fig. 2c ). Genomic distribution analysis showed that DDX5 and Fra-1 binding was mainly identified in intronic and intergenic regions, with only 10% Fra-1 and 16% DDX5 identified binding regions corresponding to within 5 kb of promoters (Fig. 2d) . Interestingly, the Fra-1/DDX5-shared binding sites were more enriched at active promoter/ 5′UTR regions, as compared to Fra-1 or DDX5 unique binding sites (Fig. 2e) . A similar phenomenon has been previously observed for ER in which ER/CTCF-shared binding were strongly promoter-enriched compared to the binding of ER alone [28] . Overlap of the Fra-1 or DDX5 binding in intergenic regions with FANTOM5 permissive enhancers [29] resulted in 2729 (21%) Fra-1 and 450 (17%) DDX5 peaks that overlapped with enhancers. Motif enrichment analysis revealed that the consensus AP-1 motif was the most significantly enriched motif in unique Fra-1-binding sites and in Fra-1/DDX5-shared-binding sites (Fig.  2f ), in line with direct DNA binding of AP-1 proteins to these regions. The most prominent sequence motif associated with unique DDX5-binding sites was CTCF, in agreement with the finding that DDX5 can form a complex with CTCF [30] , which is a ubiquitously expressed zincfinger protein. Accordingly, comparing the CTCF cistrome for MCF7 cells [31] with the unique DDX5-or Fra-1-binding sites identified in this study indicated that the overlap was 29% and 12% with the DDX5-and Fra-1-binding sites, respectively (Fig. 2g) . Together, these results provide evidence for a mechanism of DDX5 recruitment to DNA through interaction with Fra-1.
DDX5 modulation of Fra-1 target genes
To address any gene regulatory cross talk between DDX5 and Fra-1, we performed RNA profiling of BT549 cells after depleting Fra-1 or DDX5. Both protein and mRNA levels of Fra-1 and DDX5 were efficiently reduced by Fra-1 knockdown (KD) and DDX5 KD, respectively (Supplementary Fig. 3a) . We observed changed expression of 1662 genes and 1596 genes after Fra-1 or DDX5 KD (P < 0.01 and fold change >1.5), respectively (Fig. 3a) . Of 1207 genes upregulated by Fra-1 KD, 531 genes are upregulated by DDX5 KD (Group 1 in Fig. 3b ) while 3 genes are downregulated by DDX5 KD (Group 2 in Fig. 3b ). Among 455 genes that are downregulated by Fra-1 KD, 90 genes are downregulated (Group 3 in Fig. 3b ) and 11 genes are upregulated (Group 4 in Fig. 3b ) by DDX5 KD. Importantly, co-regulated genes are over-represented for genes regulated in the same direction (531 upregulated and 90 downregulated genes; Fig. 3b ). The co-regulated genes in Group 1 are associated with biological processes including immune response, cell adhesion, and negative regulation of cell proliferation (Fig. 3c) . Genes related to negative regulation of cell proliferation such as CLCA2 and KLF4 are upregulated in Fra-1 KD and DDX5 KD cells (Fig. 3d, e) . The co-regulated genes in Group 3 are closely related to cell cycle regulation and positive regulation of survival gene Fig. 1 Identification of endogenous Fra-1-associated proteins by RIME. a Fra-1-associated proteins were identified by RIME in BT549 cells. The data of Fra-1 interactome are shown as a Wordcloud, in which the size of protein names corresponds to the strength of the interactions according to the T-test difference Fra-1_IgG. b Pie chart presenting the functional distribution of identified Fra-1-associated proteins (from a) based on PANTHER protein class analysis. c Peptide coverage from Scaffold for six selected Fra-1-associated proteins.
Regions of peptide coverage were represented by yellow shading and the identified post-translational modifications were shown by green shading. Prob probability, #Pep number of peptides, %Cov % protein coverage. d Validation of six Fra-1-associated proteins by coimmunoprecipitation in BT549 cells. Western blot of the immunoprecipitates with an Fra-1 antibody demonstrates the pull down of Fra-1 (bottom panel). IgG was used as a negative control Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor. . .product expression (Fig. 3c) . Cell cycle genes such as CDC45 and ORC6 are downregulated in Fra-1 KD and DDX5 KD cells (Fig. 3d, e) . Together, these data show that Fra-1 and DDX5 share a substantial number of downstream target genes and in general have consistent effects on gene expression.
DDX5 functions as a transcriptional coactivator for Fra-1 in TNBC cells
We performed a luciferase assay with AP-1 reporter constructs in MCF7 cells, which express AP-1 proteins at low levels. Ectopic expression of the AP-1 family members, Fra-1 together with c-Jun, increased the reporter gene activity, confirming that this activity is dependent on AP-1 expression (Fig. 4a) . Moreover, overexpression of DDX5 increased AP-1-dependent transcriptional activation (Fig. 4a) , and KD of DDX5 reduced the activation (Fig. 4b) . In both cases, the effect was dose-dependent. These findings support that DDX5 functions as a coactivator of AP-1. To assess whether DDX5 co-activates endogenous AP-1-regulated genes, we performed qPCR on CLCA2, KLF4 and ORC6, which contain shared Fra-1/DDX5-binding sites. These genes are significantly affected by TPA ( Supplementary Fig. 3b ), which is a potent activator of AP-1, indicating that they are direct target genes of AP-1. In accordance with our RNAseq data, CLCA2 and KLF4 are upregulated and ORC6 is downregulated by either DDX5 KD or Fra-1 KD (Fig. 4c) . Moreover, combining KD of DDX5 and Fra-1 resulted in a further increase of CLCA2 and KLF4 and further decrease of ORC6 expression, compared with only KD of DDX5 or Fra-1 (Fig. 4c) . Importantly, KD of Fra-1 had no effect on the expression of DDX5 and vice versa ( Supplementary Fig.  3a) . We further investigated the relationship between Fra-1 and DDX5 recruitment to regions co-occupied by both Fra-1 and DDX5 in CLCA2, KLF4, and ORC6. ChIP-qPCR assays showed that Fra-1 KD (Supplementary Fig. 3c ) decreased DDX5 enrichment at these sites (Fig. 4d) , while not affecting DDX5 enrichment at DDX5 unique binding sites in SCXB and MESP2 (Supplementary Fig. 3d ). However, DDX5 KD ( Supplementary Fig. 3c ) did not affect Fra-1 binding at these three binding regions ( Supplementary Fig.  3e ). Together, our analyses show that DDX5 functions as a transcriptional coregulator for Fra-1 and that DDX5 requires Fra-1 binding for its recruitment to common genomic targets.
DDX5 enhances Fra-1-dependent growth of TNBC cells
We and others have demonstrated that Fra-1 KD decreases the proliferation of TNBC cells [1, 11] . To assess whether DDX5 is important for Fra-1-driven cell growth, we carried out Fra-1 or DDX5 KD as well as double KD of DDX5 and Fra-1 in BT549 cells. As expected, the growth and colony-forming ability of Fra-1-depleted cells were significantly reduced compared with that of controls (Fig. 4e, f) . DDX5 depletion reduced cell growth, and importantly cooperated with Fra-1 depletion to further suppress cell growth (Fig. 4e, f) . Collectively, these findings suggest that DDX5 promotes cell growth and enhances Fra-1 effect on cell growth.
Identification of candidate direct target genes of DDX5 interaction with chromatin
We integrated ChIP-seq and RNA-seq data to identify direct target genes of DDX5 interaction with chromatin. The DDX5 binding sites (<10 kb) were filtered for those showing a significant decrease or increase in mRNA levels (fold change >1.5, P < 0.01) following DDX5 KD. This revealed 220 downregulated and 260 upregulated genes (Fig. 5a ). Gene Ontology analysis of these direct DDX5 target genes showed that these are related to important tumor characteristics such as "regulation of cell proliferation", "regulation of cell migration", and "regulation of cell adhesion" (Fig. 5b) , consistent with our finding that DDX5 promotes cell growth (Fig. 4e, f) . Analysis of the Gene Expression-Based Outcome for Breast Cancer (GOBO) dataset revealed that the direct upregulated gene set of DDX5 KD (220 genes) is significantly associated with poor outcome, whereas the direct upregulated gene set of DDX5 KD (260 genes) predicts good outcome (Fig. 5c) . We then manually curated from the published literature a list of DDX5 direct target genes involved in regulation of cell proliferation. Cells upon DDX5 KD showed a preferential down-regulation of proliferation-promoting genes (e.g., PLK1, CDC20) and a concomitant up-regulation of proliferation-repressing genes (e.g., CDKN2B, CEBPD) ( Fig. 5d and Supplementary Fig. 3f ). Down-regulation of PLK1 and CDC20 and up-regulation of CDKN2B were also observed upon Fra-1 KD (Supplementary Fig. 3f ). The influence of DDX5 KD on mRNA levels of selected target genes was confirmed by quantitative PCR (Fig. 5e) . Next, by ChIP-qPCR, we confirmed DDX5 binding to all four genes (Fig. 5f) . We further analyzed cell cycle distribution in DDX5-depleted cells by flow cytometry. DDX5 KD increased the G1 fraction and decreased the S fraction ( Supplementary Fig. 3g ), suggesting that DDX5 is important for G1/S progression. Collectively, these results suggest that DDX5-regulated gene networks control cell proliferation. Toward defining the clinical significance of the DDX5-regulated gene signatures, we determined the relationship between the levels of the gene set and patient outcome. Using the GOBO dataset, Kaplan-Meier survival curves show that high expression levels of the proliferation-promoting gene set correlates with poor outcome (P < 0.00001), whereas high levels of the proliferationrepressing gene set predicts good outcome (Fig. 5g) . Collectively, these results support that analysis of DDX5-regulated gene expression program in breast cancer tissue predicts clinical outcome.
DDX5 protein levels are upregulated in basal-like breast cancer
Basal-like breast cancer and TNBC describe a broadly similar group of cancers; 80% of TNBCs are basal-like. We performed immunofluorescence staining of tissue microarrays (TMAs) to examine the protein levels of DDX5 in tumor tissue and adjacent normal breast tissue. Data regarding tumor nodes and metastasis (TNM), clinical stage, and pathology grade, and IHC-staining for HER2, estrogen receptor (ER), and progesterone receptor (PR) were available. The specificity of the DDX5 antibody in immunohistochemistry was verified in BT549 cells following siRNAmediated KD of DDX5 (Supplementary Fig. 3h ). Compared with non-basal-like tumors (luminal A, luminal B, and HER2-enriched subtypes), triple-negative basal-like tumors expressed higher protein levels of DDX5 (Fig. 6a, b) . In addition, DDX5 protein levels were higher in ER− tumors than in ER+ tumors (p = 0.049) (Fig. 6b) . There was no significant difference of DDX5 expression in six normal breast tissues compared to breast tumors; no significant correlation between DDX5 expression and HER2, clinical stage and pathology grade was observed (Supplementary Table 2 ). Furthermore, we analyzed the correlation between DDX5 expression levels and patient outcome. Strikingly, by analyzing of datasets (kmplot.com), which contain relapsefree survival information, increased DDX5 expression was found to be significantly associated with poor outcome among ER− breast cancer patients (n = 801) and among all patients (n = 3951) but not among ER+ breast cancer patients (n = 2061) (Fig. 6c) . Together, these findings support DDX5 as a marker of poor outcome in ER− breast tumors.
Discussion
Here we report, for the first time, the Fra-1 chromatin interactome in TNBC cells, important in deciphering molecular mechanisms of Fra-1 signaling in TNBC. The AP-1 transcription factor is closely related to cell proliferation, differentiation, and apoptosis, which makes it relevant in studies of the development and progression of cancer. In particular, the AP-1 protein member Fra-1 is highly expressed in TNBC, which is a form of breast cancer with a worse outcome than other breast cancer subtypes. As the Fra-1 regulation of downstream targets is influenced by associated coregulators, alterations in Fra-1 protein complex composition may have direct clinical implications. Here, we performed purification of endogenously expressed Fra-1 transcriptional complexes to identify chromatin-bound partners of Fra-1 in TNBC cells. We identified several groups of functionally related proteins that are associated with Fra-1. These include DNA repair proteins such as XRCC5, XRCC6, and RPA1, consistent with a role for AP-1 in induction of repair genes following genotoxic stress [32] . Furthermore, Fra-1 associates with multiple mRNA processing/splicing proteins. Indeed, growing evidence indicates that many DNA-binding proteins directly interact with RNA to influence RNA transcription and posttranscriptional regulation [33] . Of this group, THRAP3 has been previously identified as a coactivator for AP-1 [34] . Other Fra-1-associated proteins are involved in transcription regulation. These encompass well-characterized coactivators, such as NCOA5, KHDRBS1, and NONO, and transcription factors, for example BCLAF1 that contains homologies to the basic zipper (bZIP) and Myb DNAbinding domain and can bind to DNA [35] . Thus, Fra-1 interacts with diverse functional classes of proteins in TNBC cells that could reflect the diversity of AP-1 functions. However, we noted that the RIME method did not detect all known interacting proteins, as has been reported in other studies [36] [37] [38] . For example, although we found the enrichment for the TEAD-binding motif in Fra-1-binding sites, the TEAD family of transcription factors was not detected. The failure to detect these proteins may be caused by their low abundance and low affinity, poor signal detection by mass spectrometry, or poor recovery from stringent denaturing/high salt washes. Fig. 4 a-c DDX5 functions as a transcriptional coactivator for Fra-1 in triple-negative breast cancer (TNBC) cells. a DDX5 activates 2xTRE luciferase reporter gene in a dose-dependent manner. Co-transfection of 2xTRE luciferase reporter plasmids without or with pCMV6-Fra-1 and pCMV6-c-Jun, together with increasing amount of pCMV6-DDX5 as indicated was carried out in MCF7 cells. Data are shown as means with SD from three independent experiments performed in triplicate. ** P < 0.01 and * P < 0.05 by Student's t-test. The dosedependent overexpression of Myc-tagged DDX5 was verified by western blot analysis using anti-c-Myc antibody. Vinculin was used as a loading control. b MCF7 cells were transfected with the increasing amount of DDX5 siRNA (siDDX5) or control siRNA (sicontrol) as indicated for 48 h, followed by transfection of 2xTRE luciferase reporter plasmids, and pCMV6-Fra-1 and pCMV6-c-Jun together. Data are shown as means with SD from three independent experiments performed in triplicate. *** P < 0.001, ** P < 0.01, and * P < 0.05 by Student's t-test. The knockdown of DDX5 was verified by western blot analysis using the anti-DDX5 antibody. Vinculin was used as a loading control. c BT549 cells were transfected with Fra-1 siRNA (siFra-1) or DDX5 siRNA (siDDX5) individually, or co-transfected with siFra-1 and siDDX5 for 72 h. mRNA levels of CLCA2, KLF4, and ORC6 were measured by quantitative reverse transcriptase PCR. The means ± SD for three independent experiments performed in triplicate.
*** P < 0.001, ** P < 0.01 and * P < 0.05 by Student's t-test. d ChIP-qPCR analysis of the recruitments of DDX5 to CLCA2, KLF4, and ORC6 after KD of Fra-1. Data are represented as fold enrichment relative to IgG and shown as means with SD from three independent experiments performed in triplicate. * P < 0.05 by Student's t-test. e, f DDX5 enhances Fra-1-dependent growth of TNBC cells. e BT549 cells were transfected with control siRNA (sicontrol), siFra-1, or siDDX5 individually, or co-transfected with siFra-1 and siDDX5, followed by clonogenic cell survival assays. Representative images (magnification ×10) are shown. Quantification results of clonogenic cells analyzed from three independent experiments are shown. The absorbance of control siRNA-transfected cells was used for normalization. *** P < 0.001 compared with control siRNA, # P < 0.05 represents the differences between siFra-1 and double KD of Fra-1 and DDX5. f WST-1 assay was performed following individual or combined transfection of siFra-1 or siDDX5 and measured at day 0 and day 4. Absorbance of day 0 was used for normalization Among the most enriched Fra-1-interacting proteins was the RNA helicase DDX5. DDX5 belongs to the DEAD-box protein family of RNA helicases. Among its functions are RNA processing and regulation of transcription, translation, and cell proliferation. The connection of DDX5 to Fra-1 action is supported by the high genome-wide co-occupancy of Fra-1 and DDX5 on chromatin. Moreover, we show that Fra-1 and DDX5 share many downstream target genes required for TNBC cell growth, such as the cell cycle genes CDC45 and ORC6. We demonstrate that DDX5 increases Fra-1-driven TNBC cell proliferation and colony formation. Finally, we identify DDX5 as a coregulator for Fra-1, which enhances AP-1 transcriptional activity, consistent with previous reports showing that DDX5 acts as a transcriptional coregulator for various transcription factors. Upon Fra-1 depletion, the expression of 455 genes is repressed suggesting an activator role for Fra-1. However, the KD of Fra-1 also increased the expression of 1207 genes, indicating that Fra-1 could be a repressor for a set of target genes. It has been shown that the same transcription factor can function as either an activator or a repressor subjected to its interaction with specific coregulators and/or its binding sequence [39] . Of the genes regulated by DDX5 KD, a subset of genes was upregulated, indicating a putative corepressor function for DDX5. Similarly, other coregulators such as TLE3 [40] have been discovered to act both as transcriptional coactivators and corepressors depending on DNA context. Specific protein-protein interactions on a particular target gene to which DDX5 was interacted may determine whether DDX5 acts as a coactivator or corepressor.
DDX5 is highly expressed in a number of solid cancers such as prostate, colon, and breast cancer [23] [24] [25] , although its in vivo targets are not fully characterized. We identify DDX5 direct target genes in TNBC cells. We found that DDX5 depletion impairs gene expression of the prereplication complex such as ORC1, ORC6, and CDC6 and CMG subunits including MCM2, MCM5, and CDC45, thereby suppressing cell proliferation. These data are consistent with a recent study demonstrating that genes affected by DDX5 KD in colorectal cancer cells are mainly associated with the DNA replication gene ontology group [22] . These results suggest that DDX5 confers a significant advantage to cancer cell proliferation. In support of this, analysis of DDX5-regulated gene expression set in breast cancer tissue predicts clinical outcome. This is the first genome-wide map of DDX5-binding sites in TNBC cells. De novo motif analysis of DDX5-binding sites implicated involvement of AP-1, CTCF, and Smad4 in mediating DDX5 binding. Previous studies have shown that DDX5 can form a complex with CTCF and Smad4 [30, 41] , suggesting that CTCF and Smad are likely cooperating transcription factors for DDX5 DNA binding. Interestingly, DDX5 interacts with CTCF and cohesins, and a mechanism that DDX5 may be involved in 3D organization of chromatin loops in the nucleus has been proposed [30] .
Data regarding the clinical significance of DDX5 in TNBC are limited. In this study, we show that DDX5 protein expression is upregulated in basal-like breast cancer compared to non-basal-like tumors, and higher in ER− tumors compared to ER+ tumors. Consistently, analyses of DDX5 protein expression patterns in a panel of 45 breast cancer cell lines revealed that DDX5 expression increased gradually from luminal to basal subtypes [25] . Thus, high expression of DDX5 is correlated with the more aggressive basal subtypes. We have previously shown that Fra-1 is also highly expressed in basal-like breast cancers [11] . Thus, given the overexpression of both Fra-1 and DDX5 in triplenegative basal-like tumors, connected to our in vitro experimental findings, it is highly likely that DDX5 promotes Fra-1-regulated breast cancer growth by enhancing its transcriptional activity. As there is no effective targeted therapy for TNBC, there is an urgent requirement for novel strategies against this tumor subtype. Therefore, targeting the transcriptional coregulator DDX5 might be a novel strategy to treat this tumor subtype.
In summary, we elucidate for the first time the chromatin-associated Fra-1 interactome in TNBC cells. The results of our study identify an important role for DDX5 as a regulator of AP-1-mediated gene expression in TNBC. Our finding that DDX5 was required for the growth of TNBC cells suggests that strategies to interfere with this function may be of therapeutic benefit.
Methods
Cell lines, siRNA, and plasmids BT549, Hs578T, MDA-MB-231, and MCF7 cell lines were purchased from the American Type Culture Collection. BT549 and MDA-MB-231 cells were cultured in RPMI- For overexpressing Fra-1, c-Jun, or DDX5, cells were transfected with pCMV6-Fra-1 (RC202104, ORIGENE), pCMV6-c-Jun (RC209804, ORIGENE), or pCMV6-DDX5 (RC200371, ORIGENE) expressing vectors using lipofectamine 2000 (Invitrogen; Life Technologies). RIME RIME was performed as previously described [42] . Immunoprecipitation was performed using anti-Fra-1 (R-20; sc-605) or IgG (sc-2027) antibody from Santa Cruz Biotechnology. Bead-bound proteins were digested by trypsin. Liquid chromatography-mass spectrometry using an UltiMate 3000 LC (Thermo Scientific) combined with a Q-Exactive-HF mass spectrometer (Thermo Scientific) [43] in the Core Facility of Mass Spectrometry and Proteomics (ZMBH, Germany) was used to analyze peptides.
Data were analyzed by using MaxQuant version 1.5.3.30 [44] and searched against a human specific database extracted from UniProt (UniProt Consortium). Results were filtered to FDR <1% on peptide spectrum match and protein level. The self-compiled R-scripts were used to process and filter MaxQuant output files and statistical analysis of the data was carried out with the Perseus Software [45] . For statistical testing MaxQuant-generated LFQ values were logarithmized and filtered for proteins that contained LFQ values for at least two out of three replicates in one condition. Missing values were subsequently replaced with imputed values from normal distributed values with Perseus default settings (width = 0.3, down shift = 1.8). T-tests were carried out for each combination of conditions.
ChIP and ChIP-seq
ChIP was performed as previously described [46] . Anti-DDX5 (ab21696; Abcam), anti-Fra-1 (R-20, sc-605), and normal rabbit IgG (sc-2027) antibodies were used in these approaches. qPCR was performed to quantify immunoprecipitated DNA.
Identification of significantly enriched peak regions against input and annotation of peaks were carried out by Model-based Analysis of ChIP-seq and HOMER software, respectively [47] . The enriched peaks were used for identifying de novo and known motifs by HOMER software, which was also used to generate peak intensity heat maps. ChIP-seq data are deposited in GEO (accession number GSE112963).
RNA-seq
RNA-seq experiments were performed in BT549 cells. RNA was extracted 3 days after transfection with siFra-1, siDDX5, or control siRNA. Experiments were performed in triplicates for each condition. Library construction and sequencing were performed following the manufacturer's protocol. Libraries were sequenced as paired-end, 100-bp reads on an Illumina HIseq 2500 and aligned to the GEN-CODE V19 GTF annotation using TopHat (v2.0.12) [48] . Read counts were then obtained using HT-seq (v0.6.1). Differential expression analysis was performed using the DESeq 2 workflow. Data are deposited in GEO (accession number GSE112963).
Cell proliferation assay
Cell proliferation was measured at day 0 and day 4 using the WST-1 reagent (Roche Applied Science) following the recommendations from the manufacturer.
Clonogenic cell survival assay
Cells were seeded in six-well plates (4000 cells/well) and grown for 7 days. Fixation, staining, and quantification were described previously [49] .
Quantitative reverse transcriptase PCR
Experimental procedures for quantitative reverse transcriptase PCR with Fast SYBR Green Master Mix, which was purchased from Applied Biosystems, were previously described [50] .
Reporter gene assay
Reporter gene assay with 2xTRE luciferase reporter plasmids in MCF7 cells was performed as described previously [11] . For protein overexpression, pCMV6-Fra-1, pCMV6-cJun, pCMV6-DDX5, or empty vector was transfected together with 2xTRE luciferase reporter plasmid in 24-well plates. Dual-Luciferase Report assay kit (Promega) was used to measure luciferase activity.
Western blot analysis
Western blotting was performed as described elsewhere [46] . Primary antibodies used in this study were anti-Fra-1 (R-20; sc-605) and anti-Vinculin (H-10; sc-25336); anti-cJun (G-4; sc-74543), anti-KHDRBS1 (H-4; sc-514468), anti-THRAP3 (sc-133250), anti-c-Myc (9E10), and anti-PARP1 (F-2; sc-8007) from Santa Cruz Biotechnology; and anti-DDX5 (ab21696), anti-SAFB (ab187650), and anti-SFPQ (ab38148) from Abcam.
Co-immunoprecipitation
Co-IP was performed as previously described [49] . Cell lysates were immunoprecipitated with anti-Fra-1 (R-20; sc-605), anti-c-Jun (H-79; sc-1694), or IgG (sc-2027) antibody, and analyzed by western blot analysis.
Flow cytometry
Flow cytometry was carried out to analyze cell cycle. BT549 cells (8 × 10 5 ) were seeded in 10-cm dishes and allowed to attach overnight. Following morning, cells were transfected with control siRNA or DDX5 siRNA. After 4 days, cells were harvested by trypsinization and fixed with 70% cold ethanol for 30 min. After washing the fixed cells by cold phosphate-buffered saline (PBS), cells were stained with 50 μg/ml propidium iodide supplemented with RNase A (Sigma) for 30 min at 37°C, followed by fluorescenceactivated cell sorting (FACS) analysis using a FACS Calibur flow cytometer (BD). Cell cycle analysis was performed using CELLQuest program (BD).
Immunofluorescence staining BT549 cells were transfected with control siRNA or DDX5 siRNA. After 48 h, cells were plated in four-well chamber slides. The following day, cells were fixed (4% PFA), permeabilized (0.1% Triton X-100), and blocked (1% bovine serum albumin in PBS). The blocked BT549 cells were immunostained with anti-DDX5 antibody (HPA020043; Sigma-Aldrich) at a dilution of 1:50. To analyze the DDX5 protein expression level in human breast cancer samples, immunofluorescence staining was performed for TMAs (US BioMax, BR1503e) [49] . Staining was undertaken as above. A Nikon high speed spinning disk microscope was used to capture images separately. ImageJ was used to quantitate staining for each tissue case.
Statistical analysis
Data shown are the means with standard deviations (SD) from three independent experiments performed in triplicate. For comparing differences between two groups, unpaired two-tailed Student's t-test was used. For comparing differences among three or more groups, one-way ANOVA was used.
